To evaluate the one-year efficacy and safety of photodynamic therapy (PDT) combined with intravitreal injections of ranibizumab for polypoidal choroidal vasculopathy (PCV).
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1, 2 As a unique form of choroidal neovascularization (CNV), [3] [4] [5] polypoidal choroidal vasculopathy (PCV) is characterized by a branching vascular network that terminates in polypoidal lesions. [6] [7] [8] [9] Similar to AMD, 10 recent findings of high concentrations of VEGF in aqueous humor 11 and high expression of VEGF in histologic specimens of PCV 12 have suggested that VFGF is involved also in the pathogenesis of PCV. In contrast to AMD, however, it has been reported that the treatment effects of anti-VEGF agents on the vascular lesions associated with PCV are limited. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] In a recent report of PCV by Hikichi and associates, 25 although exudative changes regressed with three monthly injections of ranibizumab, with concomitant improvement of visual acuity (VA), complete disappearance of the polypoidal lesions was achieved in only 26% of eyes.
A number of studies have shown encouraging results of photodynamic therapy (PDT) on PCV. [26] [27] [28] [29] [30] In a report by Chan and associates, 27 PDT led to complete regression of the polypoidal lesion in 95% of eyes with PCV, and resulted in stable or improved VA one year after treatment. Unfortunately, one or more years after successful treatment with PDT, some eyes have a recurrence of the PCV lesions and, consequently, a decrease in VA. 31, 32 Akaza and associates 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Photodynamic Therapy with Ranibizumab. Tomita K, et al. Page 3 been successfully treated with PDT showed a recurrence of the polypoidal lesions during a follow-up of 24 months. These recurrent polypoidal lesions are often accompanied by an exudative change, which results in a poor visual prognosis in spite of retreatment using PDT.
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Several investigators have reported promising short-term results of PDT combined with bevacizumab for the treatment of PCV. [34] [35] [36] [37] [38] Recently, Ruamviboonsuk and associates 39 reported one-year results of 12 eyes with PCV that were treated with PDT combined with ranibizumab. To date, however, the efficacy and safety of this combined therapy has not been sufficiently evaluated. 37 In addition, most reports have involved PCV that had no previous treatments. 23, 35, 36, 39 In the clinical setting, physicians often need to treat eyes in which PCV has recurred after initial treatment with PDT or eyes with chronic PCV that is refractory to anti-VEGF agents, 31-33 but, again, little information is available on the efficacy of combined therapy in such cases. 34 Accordingly, the study described herein was designed to study the safety and efficacy of PDT combined with ranibizumab for the treatment of symptomatic PCV, depending on the history of previous 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Photodynamic Therapy with Ranibizumab. Tomita K, et al. Page 4 
PATIENTS AND METHODS
For this case series, we studied retrospectively the medical records of 66 consecutive eyes (63 patients) with subfoveal PCV that were treated with PDT combined with intravitreal injections of ranibizumab (Lucentis; Novartis, Bülach, Switzerland) at Kyoto
University Hospital between the beginning of May 2009 to the end of February 2011.
Inclusion criteria of the study were (1) symptomatic subfoveal PCV, (2) presence of exudative or hemorrhagic features involving the macula, (3) VA of 0.7 or less on a Landolt chart before treatment, and (4) a minimum follow-up of 12 months after the initial treatment. The diagnosis of PCV was based on indocyanine green angiography, which shows a branching vascular network that terminates in polypoidal swelling. In the current study, all eyes showed a polypoidal lesion, a branching vascular network, or type 2 CNV beneath the foveal center. Eyes with other macular abnormalities (i.e., AMD, pathologic myopia, idiopathic CNV, presumed ocular histoplasmosis, angioid streaks and other secondary CNV) were excluded from the study. However, pseudophakic eyes were included, but eyes with a history of vitrectomy were excluded. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Photodynamic Therapy with Ranibizumab. Tomita K, et al. Page 5 determination of intraocular pressure, indirect ophthalmoscopy, slitlamp biomicroscopy with a contact lens, spectral-domain optical coherence tomography (OCT) (Spectralis HRA+OCT, Heidelberg Engineering, Heidelberg, Germany), and fluorescein and indocyanine green angiography (HRA-2, Heidelberg Engineering). Patients who had a visual disturbance due to PCV were offered PDT combined with an intravitreal injection of 0.5 mg ranibizumab. Injections of ranibizumab were performed in a sterile manner and prophylactic topical antibiotics were applied for 1 week after the injection. At 3-4 days after the intravitreal injection of ranibizumab, normal-fluence PDT was performed using a 689 nm diode laser unit (Visulas PDT system 690S; Carl Zeiss, Dublin, California) after an injection of verteporfin (Visudyne; Novartis), according to PDT guidelines for AMD.
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The greatest linear dimension chosen was based on fluorescein and indocyanine green angiograms, as previously described. 28 All polypoidal lesions and the entire branching vascular network detected with indocyanine green angiography and type 2 CNV detected with fluorescein angiography were included. Serous pigment epithelial detachment was not included in the lesion area when the absence of underlying CNV was confirmed.
After the initial treatment, each patient was scheduled for an examination at 3 months, at which time they again underwent a comprehensive ophthalmologic examination. When indocyanine green angiography showed recurrent or residual 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Photodynamic Therapy with Ranibizumab. Tomita K, et al. Page 6 polypoidal lesions and when an exudative change was seen on OCT, additional combination therapy was given. When residual polypoidal lesions were detected on indocyanine green angiography but no exudative change was seen on OCT, no additional treatment was given and the patient was reevaluated at the next visit. When only recurrent or residual exudative changes due to PCV were seen by OCT examination but neither polypoidal lesions nor type 2 CNV were seen on angiography, an additional injection of ranibizumab was given. After the additional injection of ranibizumab, the patient was scheduled to visit our clinic after one month, at which time they again underwent a comprehensive ophthalmologic examination. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Photodynamic Therapy with Ranibizumab. Tomita K, et al. Page 7 All values are presented as mean ± standard deviation. For statistical analysis, best-corrected VA as measured with a Landolt chart was converted to a logarithm of the minimum angle of resolution (logMAR). VA was considered to be improved or deteriorated when the logMAR change was greater than 0.3. On OCT sections, foveal thickness was defined as the distance between the inner surface of the neurosensory retina and the retinal pigment epithelium beneath the fovea. In each group, VA or foveal thickness after the combined therapy was analyzed by one-way repeated measures analysis of variance with the Dunnett method. At each time point, the change in VA or in foveal thickness was analyzed using the least significant difference procedure. Software (StatMate III; ATMS, Tokyo, Japan) was used for the statistical analyses. A P value < .05 was considered to be statistically significant. eyes, respectively. Of the 12 eyes with a serosanguineous pigment epithelial detachment, 10 showed a reduction of its size and 5 showed complete resolution at three months. Of 24 eyes examined at three months with indocyanine green angiography, the polypoidal lesion was reduced in size in all eyes and had disappeared completely in 19 eyes (79.1%) (Figures 1 and 2 ). However, a branching vascular network remained in all eyes. Figure 3 shows the change in VA and in foveal thickness after treatment of the treatment-naïve group. Combined therapy reduced substantially the exudative change immediately after initiation of treatment. The foveal thickness was reduced significantly from 390.3 ± 143.2 µm before treatment to 252.9 ± 104.3 µm (P < .01) at three months, and to 227.4 ± 50.3 µm (P < .01) at 12 months. The mean VA before treatment (0.47 ± 0.37) also improved significantly, being 0.32 ± 0.30 (P < .01) at three months. The improvement of VA was maintained until 12 months (0.29 ± 0.29, P < .01). At 12 months, significant improvement of VA was seen in 10 eyes (34.5%) and deterioration of VA was seen in one eye (3.5%) (Figure 4 ). Over this 12-month period, additional combined therapy to residual polypoidal lesions with an exudative change was performed in 9 eyes (31.0%). If only an exudative change remained, additional ranibizumab injections were given (7 eyes; 24.1%). In the treatment-naïve group, although two eyes showed subretinal hemorrhage (larger than 4 disc areas) after the combined therapy, the hemorrhage was absorbed spontaneously with no decrease in VA ( Figure 5 ). During this 12-month period, no other serious adverse event was seen in the treatment-naïve group.
In the anti-VEGF group, combined therapy reduced substantially the exudative change. The mean foveal thickness was reduced significantly from 434.8 ± 243.2 µm before treatment to 276.1 ± 148.9 µm (P < .05) at three months, and to 311.4 ± 166.7 µm (P < .05) at 12 months. The mean VA was improved from 0.51 ± 0.36 before treatment to 0.39 ± 0.37 at three months and to 0.40 ± 0.46 at 12 months, although this improvement was not statistically significant. At 12 months, significant improvement of VA was seen in three eyes (30.0%) while significant deterioration was seen in one (10.0%). During the first 12 months, additional combined therapy was performed in four eyes (40.0%) and additional ranibizumab injections were given in one eye (10.0%). During 12 months, no serious adverse event was seen in any eye of the anti-VEGF group.
In the PDT group, combined therapy reduced substantially the exudative change.
The mean foveal thickness was reduced significantly from 399.3 ± 211.8 µm before treatment to 266.0 ± 95.2 µm (P < .01) at three months, and to 318.0 ± 140.6 µm (P < .01) at 12 months. With treatment, however, the mean VA did not improve throughout the follow-up period. The mean VA (0.61 ± 0.45 before treatment) remained 0.61 ± 0.46 at three months and deteriorated somewhat to 0.68 ± 0.52 at 12 months ( Figure 6 ). At 12 months, significant improvement of VA was seen in only three eyes (11.1%) while significant deterioration was seen in five (18.5%). During 12 months, additional combined therapy was performed in eight eyes (29.6%) and additional ranibizumab injections were given to in two eyes (7.4%). In this PDT group, three eyes showed extensive subretinal hemorrhage after treatment. Of these, two developed vitreous hemorrhage and underwent pars plana vitrectomy. Table 2 shows the change in VA and foveal thickness from pretreatment values in each group. No difference was seen in the change of foveal thickness among the three groups. In addition, no significant difference was seen in the change of VA between the treatment-naïve group and the anti-VEGF group. However, change of VA in the PDT group was significantly worse than that of the treatment-naïve group at three months and thereafter (P < .05). However, even with monthly injections, reduction of the polypoidal lesion was achieved in only 33% of eyes, and the branching vascular network remained in all eyes. While anti-VEGF agents can reduce the exudative change due to PCV, often resulting in VA recovery, their effect on the reduction of the vascular lesions of PCV appears limited.
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In contrast, a number of studies have shown encouraging results of PDT for the vascular lesions of PCV, 26-30 and complete regression of the polypoidal lesions is usually achieved with a small number of PDT sessions. [26] [27] [28] [29] [30] In a report by Chan and associates, 27 PDT resulted in complete regression of polypoidal lesion in 95% of eyes with PCV.
Furthermore, visual recovery after PDT is reported to be more favorable in eyes with PCV 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 65 Using PDT combined with ranibizumab in treatment-naïve PCV eyes of our patients, Recently, a randomized prospective study (EVEREST study) has shown the 6-month efficacy of PDT in combination with ranibizumab for PCV (Lai TY, et al. IOVS 2010;51:ARVO E-Abstract 2228). In that study, complete regression of polypoidal lesions was achieved at 6 months in 77.8% after combination therapy, in 71.4% after PDT alone, and in 28.6% after intravitreal injections of ranibizumab. The mean change in VA at 6 months was +10.9, +7.5, and +9.2 for the combination therapy, PDT, and ranibizumab 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Photodynamic Therapy with Ranibizumab. Tomita K, et al. Page 15 groups, respectively; PCV eyes treated with PDT combined with ranibizumab achieved the highest gains of VA at 6 months. Our results in the treatment-naïve group are quite similar to those of the combination group in the EVEREST study. However, because the current study is retrospective, it is difficult to compare strictly our results with those of the EVEREST study.
In the study described herein, PCV that recurred after previous PDT did, indeed,
show a reduction of exudative change, but this did not result in further visual recovery, an observation similarly reported by Romano and associates, 34 who observed that in eyes with PCV that were refractory to treatment by PDT alone, PDT combined with bevacizumab resulted in morphologic stabilization of the PCV lesions, but not in visual recovery. 34 The reason for the poor change in VA seen in the PDT group after the combined therapy is unclear, although damage of the choriocapillaris or retinal pigment epithelium due to previous PDT might be involved. Rather, recent reports have shown the association of some genetic factors to the response to PDT and to subsequent visual prognosis in eyes with PCV. 43, 44 Originally, PDT group might consist of the eyes that have genetically poor VA prognosis.
To date, limited information is available on combined therapy for PCV that is refractory to anti-VEGF therapy. The current study has shown that some visual recovery bevacizumab. In the current study, two eyes in the treatment-naïve group had an extensive subretinal hemorrhage (larger than 4 disc areas) after such combined therapy, although the hemorrhage was absorbed spontaneously with no decrease in VA. In addition, three eyes in the PDT group had an extensive subretinal hemorrhage after treatment, and this resulted in vitreous hemorrhage in two eyes, so it is uncertain whether or not combined therapy actually reduces the posttreatment hemorrhagic complications.
However, similar to PDT alone, even if PDT is combined with anti-VEGF agents, physicians need to keep in mind the risk to their patients of these complications.
Major limitations of the current study are its retrospective nature, its small sample size, and its lack of control individuals. Furthermore, we used a Landolt chart, which is based on an uneven spatial gradient scale, for the measurement of VA. However, despite these shortcomings, our findings suggest that PDT combined with intravitreal injections of ranibizumab results in rapid regression of the polypoidal lesions and exudative changes, and often results in improvement of VA in eyes with treatment-naïve PCV.
Patients with PCV treated with PDT combined with ranibizumab do have a risk of posttreatment hemorrhagic complications. However, because our findings are based on an observation period of only 12 months, it remains unclear whether or not PDT in combination with ranibizumab reduces the recurrence rate of PCV. Because the long-term efficacy of PDT alone is not as promising as was thought initially, prospective long-term studies are needed to determine the efficacy and safety of combined therapy for PCV. 12. Matsuoka M, Ogata N, Otsuji T, Nishimura T, Takahashi K, Matsumura M.
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Visual acuity was considered to be improved or deteriorated when the change (logMAR) was greater than 0.3. 
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In eyes with polypoidal choroidal vasculopathy, photodynamic therapy combined with intravitreal injections of ranibizumab substantially diminished the polypoidal lesion and reduced the exudative change. This combined therapy led to significant visual recovery in eyes with polypoidal choroidal vasculopathy that were treatment-naive, but not in eyes with polypoidal choroidal vasculopathy that had recurred after previous photodynamic therapy. Photodynamic therapy in combination with ranibizumab does, however, still have a risk of the postoperative hemorrhagic complications. 
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